💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Zota Health Care Limited is an India-based pharmaceutical company, which is engaged in the manufacturing and marketing of pharmaceutical products catering to domestic and international markets. It engages in manufacturing, marketing, and exporting a range of pharmaceutical,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak business — but flagged on governance.
Zota Health Care is scored on the pharma / healthcare framework. It keeps a thin -13.6% of every rupee of sales as net profit. Free cash flow is worth about -9.7% of its market value.
Book value itself has compounded 105%/yr — the hallmark of a genuine compounder. Return on equity is a weak -18.0%.
It trades at -37× earnings. The forensic screen raises a red flag: Share count up 31% over 4 years — heavy equity dilution.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | -37.4 | — | — |
| P/B | 6.82 | 4.1 | worse |
| EV/EBITDA | — | 19.33 | — |
| ROE | -18.03 | 0.3 | worse |
| ROCE | -11.17 | 14.41 | worse |
| ROA | -10.42 | 1.64 | worse |
| Quick Ratio | 1.11 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 57% CAGR over 3 years — high-growth territory. Growth is accelerating — latest year outpaced the prior year's rate.
4 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a -31% swing — check if it's a one-off or structural.
Operating margin has compressed from -3% to -15% — costs or competition are eating into profitability. Margins have declined for 2 consecutive years — watch for a structural cost problem.
Negative ROE — the business is destroying shareholder value.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play.
4 of 4 years had negative operating cash flow — profitability on paper may not translate to cash.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 16% sequentially — momentum is building. Run-rate stepping up — recent quarters average 22% above earlier ones.
4 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 41% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (-20% → -13%) — profitability per rupee of revenue is improving.
P/E band unavailable — needs 5y of consistent EPS + price history.
Promoters at 49.4% — dispersed ownership; institutional flows drive the stock. Promoters reduced 1.3pp over 4 quarters — watch whether this is planned divestment or pledge invocations.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.